JP2007509058A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509058A5 JP2007509058A5 JP2006535367A JP2006535367A JP2007509058A5 JP 2007509058 A5 JP2007509058 A5 JP 2007509058A5 JP 2006535367 A JP2006535367 A JP 2006535367A JP 2006535367 A JP2006535367 A JP 2006535367A JP 2007509058 A5 JP2007509058 A5 JP 2007509058A5
- Authority
- JP
- Japan
- Prior art keywords
- lower alkyl
- cancer
- compound
- halo
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C(N(*)c1cc(Oc(c(*)c2)cc3c2[n](*)c(Nc2c(*)c(*)c(*)c(*)c2*)n3)ccn1)=O Chemical compound *C(N(*)c1cc(Oc(c(*)c2)cc3c2[n](*)c(Nc2c(*)c(*)c(*)c(*)c2*)n3)ccn1)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51196603P | 2003-10-16 | 2003-10-16 | |
| US60/511,966 | 2003-10-16 | ||
| PCT/US2004/034179 WO2005037273A1 (en) | 2003-10-16 | 2004-10-15 | Substituted benzazoles and use thereof as inhibitors of raf kinase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007509058A JP2007509058A (ja) | 2007-04-12 |
| JP2007509058A5 true JP2007509058A5 (2) | 2007-11-15 |
| JP4755991B2 JP4755991B2 (ja) | 2011-08-24 |
Family
ID=34465300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006535367A Expired - Fee Related JP4755991B2 (ja) | 2003-10-16 | 2004-10-15 | Ｒａｆキナーゼインヒビターとしての置換ベンゾアゾールおよびその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7423150B2 (2) |
| EP (1) | EP1682126B1 (2) |
| JP (1) | JP4755991B2 (2) |
| KR (1) | KR20060118472A (2) |
| CN (1) | CN1889951A (2) |
| AT (1) | ATE435015T1 (2) |
| AU (1) | AU2004281151A1 (2) |
| CA (1) | CA2542653A1 (2) |
| DE (1) | DE602004021838D1 (2) |
| ES (1) | ES2327418T3 (2) |
| IL (1) | IL174965A0 (2) |
| MX (1) | MXPA06004236A (2) |
| PL (1) | PL1682126T3 (2) |
| PT (1) | PT1682126E (2) |
| TW (1) | TW200526208A (2) |
| WO (1) | WO2005037273A1 (2) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME00275B (me) | 1999-01-13 | 2011-02-10 | Bayer Corp | ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE |
| EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| EP1663978B1 (en) | 2003-07-23 | 2007-11-28 | Bayer Pharmaceuticals Corporation | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| KR20060118472A (ko) * | 2003-10-16 | 2006-11-23 | 카이론 코포레이션 | 치환 벤자졸 및 ｒａｆ 키나아제의 저해제로서 그것의 사용 |
| WO2006124874A2 (en) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| CA2612693C (en) * | 2005-06-23 | 2012-05-08 | Bayer Healthcare Llc | Quantitative assays for ras p21 in body fluids |
| TWI387592B (zh) * | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
| CN101379060B (zh) * | 2006-02-10 | 2012-05-23 | 转化技术制药公司 | 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法 |
| CA2649288C (en) | 2006-04-19 | 2015-11-24 | Novartis Ag | 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling |
| AU2008254425A1 (en) * | 2007-05-21 | 2008-11-27 | Novartis Ag | CSF-1R inhibitors, compositions, and methods of use |
| BRPI0811097A2 (pt) * | 2007-05-23 | 2014-12-09 | Novartis Ag | Inibidores de raf para o tratamento de câncer de tireoide |
| CL2008001626A1 (es) * | 2007-06-05 | 2009-06-05 | Takeda Pharmaceuticals Co | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. |
| EP2181987B9 (en) | 2007-08-23 | 2014-09-03 | Takeda Pharmaceutical Company Limited | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer |
| WO2009028655A1 (ja) * | 2007-08-30 | 2009-03-05 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
| BRPI0818003A2 (pt) * | 2007-10-18 | 2019-09-24 | Novartis Ag | inibidores de csf-1r, composições e métodos de uso |
| CA2716947A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
| JP2011513332A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体 |
| JP2011513331A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤 |
| KR20100122505A (ko) * | 2008-02-29 | 2010-11-22 | 어레이 바이오파마 인크. | Ｒａｆ 저해물질 화합물 및 이들의 이용 방법 |
| US9540322B2 (en) * | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
| US8697874B2 (en) | 2008-12-01 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
| BR112012022801B8 (pt) * | 2010-03-09 | 2019-10-29 | Dana Farber Cancer Inst Inc | método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer |
| EP2661434A4 (en) * | 2011-01-06 | 2014-07-09 | Beta Pharma Canada Inc | NEW UREAS FOR THE TREATMENT AND PREVENTION OF CANCER |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| JP6342392B2 (ja) * | 2012-07-28 | 2018-06-13 | カリター・サイエンシーズ・エルエルシー | 置換型ピラゾロン化合物及び使用方法 |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| EP3623371A1 (en) | 2014-12-16 | 2020-03-18 | Axovant Sciences GmbH | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
| CN105949178B (zh) * | 2015-03-09 | 2020-05-26 | 西格莱(苏州)生物医药有限公司 | 一种苯并咪唑类化合物、其制备方法、中间体及应用 |
| CN107847494A (zh) | 2015-06-10 | 2018-03-27 | 阿考温特科学股份有限公司 | 作为α7‑烟碱乙酰胆碱受体激动剂的氨基苯并异噁唑化合物 |
| JP2018523707A (ja) | 2015-08-12 | 2018-08-23 | アクソバント サイエンシズ ゲーエムベーハー | α７−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換アミノベンゾイソオキサゾール化合物 |
| AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| CA3037587A1 (en) * | 2016-09-30 | 2018-04-05 | Epizyme, Inc. | Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors |
| WO2018146253A1 (en) | 2017-02-10 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
| CN110621316B (zh) | 2017-04-21 | 2024-01-26 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
| CA3057969A1 (en) | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
| CN108102093A (zh) * | 2017-12-19 | 2018-06-01 | 中科院广州化学有限公司 | 一种含芴及吡啶基团的二胺单体及由其合成的聚酰亚胺 |
| WO2019133810A1 (en) | 2017-12-28 | 2019-07-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| EP3877371A4 (en) | 2018-11-07 | 2022-07-27 | Dana-Farber Cancer Institute, Inc. | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| US12522583B2 (en) | 2018-11-07 | 2026-01-13 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof |
| EP3969449B1 (en) | 2019-05-13 | 2025-02-12 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| US11691963B2 (en) | 2020-05-06 | 2023-07-04 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| US12043632B2 (en) | 2020-12-23 | 2024-07-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| WO2023009708A1 (en) * | 2021-07-29 | 2023-02-02 | Ajax Therapeutics, Inc. | Heteroaryloxy triazolo- and imidazo-azines as jak2 inhibitors |
| WO2023086319A1 (en) * | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6358932B1 (en) * | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
| US5717100A (en) * | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| DE19613976C1 (de) * | 1996-04-09 | 1997-11-20 | Gruenenthal Gmbh | Thalidomid-Prodrugs mit immunmodulatorischer Wirkung |
| AU743024B2 (en) * | 1997-03-05 | 2002-01-17 | Sugen, Inc. | Formulations for hydrophobic pharmaceutical agents |
| AR012634A1 (es) * | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| GB9711650D0 (en) | 1997-06-05 | 1997-07-30 | Pfizer Ltd | Compounds useful in therapy |
| GB9716557D0 (en) * | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| US6211177B1 (en) * | 1998-11-24 | 2001-04-03 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives |
| EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP1169038B9 (en) | 1999-04-15 | 2013-07-10 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| AU7031500A (en) * | 1999-09-23 | 2001-04-24 | Astrazeneca Ab | Therapeutic quinazoline compounds |
| ATE266022T1 (de) | 2000-03-06 | 2004-05-15 | Smithkline Beecham Plc | Imidazol derivate als raf kinase inhibitoren |
| EP1332131A2 (en) | 2000-11-07 | 2003-08-06 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
| JP2004517080A (ja) | 2000-11-29 | 2004-06-10 | グラクソ グループ リミテッド | Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体 |
| US20030009034A1 (en) | 2001-03-22 | 2003-01-09 | Neil Wishart | Transition metal mediated process |
| GB0112348D0 (en) * | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
| US8299108B2 (en) * | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
| WO2003082272A1 (en) * | 2002-03-29 | 2003-10-09 | Chiron Corporation | Substituted benzazoles and use thereof as raf kinase inhibitors |
| US7531553B2 (en) * | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| KR20060118472A (ko) * | 2003-10-16 | 2006-11-23 | 카이론 코포레이션 | 치환 벤자졸 및 ｒａｆ 키나아제의 저해제로서 그것의 사용 |
-
2004
- 2004-10-15 KR KR1020067009081A patent/KR20060118472A/ko not_active Ceased
- 2004-10-15 AT AT04795357T patent/ATE435015T1/de not_active IP Right Cessation
- 2004-10-15 MX MXPA06004236A patent/MXPA06004236A/es unknown
- 2004-10-15 US US10/967,089 patent/US7423150B2/en not_active Expired - Fee Related
- 2004-10-15 DE DE602004021838T patent/DE602004021838D1/de not_active Expired - Lifetime
- 2004-10-15 ES ES04795357T patent/ES2327418T3/es not_active Expired - Lifetime
- 2004-10-15 PT PT04795357T patent/PT1682126E/pt unknown
- 2004-10-15 CN CNA2004800361998A patent/CN1889951A/zh active Pending
- 2004-10-15 WO PCT/US2004/034179 patent/WO2005037273A1/en not_active Ceased
- 2004-10-15 AU AU2004281151A patent/AU2004281151A1/en not_active Abandoned
- 2004-10-15 JP JP2006535367A patent/JP4755991B2/ja not_active Expired - Fee Related
- 2004-10-15 CA CA002542653A patent/CA2542653A1/en not_active Abandoned
- 2004-10-15 PL PL04795357T patent/PL1682126T3/pl unknown
- 2004-10-15 EP EP04795357A patent/EP1682126B1/en not_active Expired - Lifetime
- 2004-10-18 TW TW093131586A patent/TW200526208A/zh unknown
-
2006
- 2006-04-11 IL IL174965A patent/IL174965A0/en unknown
-
2008
- 2008-09-05 US US12/205,028 patent/US8415382B2/en not_active Expired - Fee Related
-
2013
- 2013-04-03 US US13/856,225 patent/US20130224195A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007509058A5 (2) | ||
| JP2007507428A5 (2) | ||
| JP2005529089A5 (2) | ||
| JP2007509059A5 (2) | ||
| JP5384611B2 (ja) | 新規ヘテロ環式化合物およびそれらの使用 | |
| EP1678166B1 (en) | Protein kinase inhibitors | |
| JP6873145B2 (ja) | ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン | |
| ES2456275T3 (es) | Derivados de quinazolina moduladores de la quinasa JAK y su uso en métodos | |
| CN114430740A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2022125283A5 (2) | ||
| ZA200305619B (en) | Substituted triazole diamine derivatives as kinase inhibitors. | |
| JP2012501312A5 (2) | ||
| JP2010510319A5 (2) | ||
| RU2009125897A (ru) | Ингибиторы фосфоинозитид-3-киназы и способы их применения | |
| ZA200603418B (en) | Substituted benzazoles and use thereof as inhibitors of Raf kinase | |
| JP5901634B2 (ja) | キナゾリン化合物及びその使用方法 | |
| JP2013516393A5 (2) | ||
| CA2671982A1 (en) | Methods of using mek inhibitors | |
| JP2008525463A5 (2) | ||
| JP2016522246A5 (2) | ||
| JP2010527373A5 (2) | ||
| JP2012519179A5 (2) | ||
| AR074575A1 (es) | Compuesto de benzoimidazol-pirimidin-aminopiridina, forma cristalina iii relacionada, formulacion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un cancer | |
| RU2017118165A (ru) | Ингибиторы энхансера гомолога 2 zestes | |
| CZ304767B6 (cs) | Substituovaný pyridin a pyridazin, farmaceutická kompozice s jeho obsahem a použití |